Slide 1: Provision to external physicians upon request
Provision to external physicians upon request Presentation (by MA/MSL) to individual or small physician group upon request Presentation at local symposia or other large audience meetings (proactive communication) Presentation during an Advisory Board Internal medical training Internal sales training
Slide 2: Rapid Fluid Resolution With Aflibercept 8 mg May Be Associated With Extended Dosing Intervals
Rapid Fluid Resolution With Aflibercept 8 mg may be Associated With Extended Dosing Intervals at Week 96 in nAMD: A PULSAR Post Hoc Analysis Michael W. Stewart,1* Paolo Lanzetta,2,3 Richard Gale,4 Javier Zarranz-Ventura,5 Sergio Leal,6 Tobias Machewitz,7 Xin Zhang,6 on behalf of the PULSAR study inv
Slide 3: Disclosures
Disclosures • Michael W. Stewart: Consultant for Alkahest and Bayer; and receives funding from Allergan, Kanghong, and Regeneron Pharmaceuticals, Inc. • PL: Consultant for Aerie Pharmaceuticals, Allergan, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, I-Care, Genentech, Novartis, Ocula
Slide 4: PULSAR: Multicenter, Double-masked Study in Patients With Treatment-naive nAMD
PULSAR: Multicenter, Double-masked Study in Patients With Treatment-naive nAMD Patients were randomly assigned (1:1:1) to receive aflibercept 8q12 (n=335), 8q16 (n=338), or 2q8 (n=336), each after 3 initial monthly injections y At W48, treatment with aflibercept 8 mg demonstrated non-inferior BCVA g
Slide 5: Analysis of Early Fluid Resolution and its Association with the Last Assigned Dosing Interval
Analysis of Early Fluid Resolution and its Association with the Last Assigned Dosing Interval at Week 96 in the Aflibercept 8-mg Groups Objective: To determine whether early fluid resolution is associated with last assigned dosing interval at W96 in patients treated with aflibercept 8 mg Methods: Th
Slide 6: Last Assigned Dosing Interval of Groups Based on Early Fluid Status
Last Assigned Dosing Interval at Week 96 of the Aflibercept 8-mg Groups Based on Early Fluid Status Last assigned dosing interval: J Q8° —§ Q12 ™§ Qi6 gy Q20 gm Q24° Fluid-free at W4 (56%; n=326) & & Fluid-free at W4 & W8 (51%; n=296) 8 & ® Fluid-free at W4, W8, & W12 (48.5%; n=283) 2Q20 2Q20 53% 54
Slide 7: BCVA and CRT Outcomes in 8-mg and 2-mg Groups Based on Early Fluid Status
BCVA and CRT Outcomes in the Aflibercept 8-mg and 2-mg Groups Through Week 96 Based on Early Fluid Status Patients who were fluid-free at Week 4 a Patients who had fluid at Weeks 4, 8, and 2 == 8&mg groups = = 2-mg group —® 8&mg groups = -@ 2-mg group Absolute BCVA (observed values) Absolute BCVA (o
Slide 8: Conclusion
* Rapid fluid resolution during the initial monthly treatment phase — particularly at Week 4 after the first injection — may be associated with extended dosing intervals in patients who received Conclusion aflibercept 8 mg for nAMD Patients in the 8-mg groups who had early fluid resolution were able